BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
ARGX upcoming catalysts
argenx: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 8 readout(s) and 0 FDA event(s). Subscribe to ARGX (.ics).
Drugs: Empasiprubart
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | argenx ARGX | NCT06284954 A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | Dermatomyositis; Myositis | active not recruiting | 3 |
| 2026-09 est. | P3 | argenx ARGX | NCT06742190 A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy (MMN); MMN | active not recruiting | 154 |
| 2026-08-12 | P2 | argenx ARGX | NCT06441682 A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | terminated | 60 |
| 2026-07-02 | P2/P3 | argenx ARGX | NCT05523167 A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis; Polymyositis; Immune-Mediated Ne | completed | 265 |
| 2026-03-11 | P3 | argenx ARGX | NCT04225156 A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | Primary Immune Thrombocytopenia | completed | 101 |
| 2026-01-12 | P3 | argenx ARGX | NCT06558279 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | Myasthenia Gravis, Ocular | active not recruiting | 141 |
| 2025-12-15 | P3 | argenx ARGX | NCT06307626 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. | Thyroid Eye Disease | terminated | 105 |
| 2025-12-15 | P3 | argenx ARGX | NCT06307613 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease | Thyroid Eye Disease | terminated | 102 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.